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Enhanced response rate to pegylated
liposomal doxorubicin in high grade serous
ovarian carcinomas harbouring BRCA1 and
BRCA2 aberrations
Robert L. Hollis1, Alison M. Meynert2, Michael Churchman1, Tzyvia Rye1, Melanie Mackean3, Fiona Nussey3,
Mark J. Arends4, Andrew H. Sims1, Colin A. Semple2, C. Simon Herrington1,4,5 and Charlie Gourley1,3*
Abstract
Background: Approximately 10–15% of ovarian carcinomas (OC) are attributed to inherited susceptibility, the
majority of which are due to mutations in BRCA1 or BRCA2 (BRCA1/2). These patients display superior clinical
outcome, including enhanced sensitivity to platinum-based chemotherapy. Here, we seek to investigate whether
BRCA1/2 status influences the response rate to single-agent pegylated liposomal doxorubicin (PLD) in high grade
serous (HGS) OC.
Methods: One hundred and forty-eight patients treated with single-agent PLD were identified retrospectively from
the Edinburgh Ovarian Cancer Database. DNA was extracted from formalin-fixed paraffin-embedded (FFPE) archival
tumour material and sequenced using the Ion Ampliseq BRCA1 and BRCA2 panel. A minimum variant allele
frequency threshold was applied to correct for sequencing artefacts associated with formalin fixation.
Results: A superior response rate to PLD was observed in patients with HGS OC who harboured variants likely to affect
BRCA1 or BRCA2 function compared to the BRCA1/2 wild-type population (36%, 9 of 25 patients versus 12.1%, 7 of 58
patients; p = 0.016). An enhanced response rate was also seen in patients harbouring only the BRCA1 SNP rs1799950,
predicted to be detrimental to BRCA1 function (50%, 3 of 6 patients versus 12.1%, 7 of 58 patients; p = 0.044).
Conclusions: These data demonstrate that HGS OC patients with BRCA1/2 variants predicted damaging to protein
function experience superior sensitivity to PLD, consistent with impaired DNA repair. Further characterisation of
rs1799950 is now warranted in relation to chemosensitivity and susceptibility to developing ovarian carcinoma.
Keywords: Ovarian cancer, BRCA1, BRCA2, PLDH
Background
Ovarian cancer represents a substantial cause of mortality
worldwide, with over 21,000 cases diagnosed, accounting
for over 14,000 deaths, per year in the United States alone
[1]. The majority of cases are ovarian carcinomas (OCs),
approximately 10–15% of which arise in patients with
inherited genetic susceptibility to disease [2, 3]. It is now
recognised that the histologically-defined subgroups of
OC represent distinct disease entities both molecularly
and clinically, with high grade serous (HGS) OC account-
ing for the majority of cases (around 70%) [4].
Germline mutations in the DNA repair genes BRCA1
and BRCA2 (BRCA1/2) are responsible for the majority of
hereditary OC, and around 15–20% harbour germline or
somatic BRCA1/2 defects [5, 6]. Mutational inactivation
of BRCA1/2 renders tumours deficient in homologous
recombination DNA damage repair (HRR) [7, 8]. BRCA1/
2-associated OC patients experience superior clinical out-
come, despite their propensity for developing visceral
metastases and a tendency to present with HGS histology
[9–13]. These tumours display superior response rates to
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multiple lines of platinum-based chemotherapy, as well as
superior sensitivity to PARP inhibitors, consistent with
HRR-deficiency and dependence upon error-prone non-
homologous end joining (NHEJ) to repair therapy-induced
DNA damage [9, 14].
Pegylated liposomal doxorubicin (PLD) is a doxorubicin
formulation, liposome-encapsulated and pegylated to in-
crease drug half-life and reduce cardiotoxicity [15, 16].
PLD is often used in OC treatment in the advanced-stage,
relapsed disease setting, with reported response rates of
around 15% when used as a single agent [17, 18]. One
mechanism of action of PLD is the induction of single-
stranded and double-stranded DNA breaks through
both free radical formation and direct intercalation
into DNA, interfering with topoisomerase II-mediated
repair [19].
A phase II trial comparing the PARP inhibitor olaparib at
two doses versus PLD in a population of BRCA1/2-mutant
patients with recurrent OC showed a greater than expected
objective response rate to PLD [20]. Because BRCA1/2
status is known to influence the response rate of pa-
tients to platinum-based chemotherapy, and induction of
DNA damage is a common mechanism of action between
PLD and platinum, we postulated that BRCA1/2 status
may also influence the response rates to PLD.
Three previous studies have attempted to address this
hypothesis, but these investigations have suffered several
methodological limitations [21–23]. All three studies in-
clude a number of untested “presumed BRCA1/2 nega-
tive” OC patients in their wild-type comparator cohorts
[21, 23]. Two studies included a significant number of pa-
tients treated with PLD in combination with other agents,
most commonly platinum, which account for around half
of the PLD-treated population in each study [21, 22]. One
study limited BRCA1/2 sequencing to regions of known
founder mutations [22], and all three studies compared
PLD response in a histologically heterogeneous population.
Furthermore, these studies have limited sequencing to
germline material, despite the substantial number of OC
known to display somatic mutational inactivation of
BRCA1/2 [24, 25]. Given the known differential chemosen-
sitivity of histological subtypes of OC [4], the clear poten-
tial for previous analyses to be confounded by superior
response rate to co-administered platinum in BRCA1/2-as-
sociated OC [9], the limited predictive power of family his-
tory in predicting germline BRCA status in the presumed
negative populations [26], and the known phenotypic over-
lap between germline and somatic BRCA1/2-inactivated
OC [24, 27], there is a clear need for comparison of re-
sponse rate to PLD monotherapy to tumour BRCA1/2 sta-
tus in a histologically uniform OC cohort.
Here we present next generation sequencing (NGS) of
tumour DNA from a cohort of OC patients treated with
PLD monotherapy from a single centre in order to better
interrogate the interaction between BRCA1/2 status and
response to PLD.
Methods
Cohort identification and pathology review
We retrospectively identified all patients treated with PLD
monotherapy between 2001 and 2014 from the Edinburgh
Ovarian Cancer Database (Fig. 1). 148 OC patients were
identified. Of these, tumour material was available for
translational research use in 119 cases. 10 μm sections
were taken from archival tissue blocks alongside a 5 μm
section to be stained with haemotoxylin and eosin (H&E).
Ethical approval for the use of tumour material was
obtained from South East Scotland Human Annotated
Bioresource (East of Scotland Research Ethics Service
Reference 10/S1402/33).
Tumour area identification and pathology review was
conducted by an expert gynaecological pathologist using
the H&E stained slide. Where histological subtype of OC
was unclear from H&E alone, a combination of patient
pathology reports and additional 5 μm sections immuno-
histochemically stained for WT1 and P53 proteins were
used to determine OC histotype.
DNA extraction
H&E stained slides were used to guide macrodissection
of four 10 μm FFPE tissue sections per specimen. DNA
extraction was performed using the QIAamp DNA FFPE
Tissue Kit and Deparaffinization Solution according to
the manufacturer’s instructions.
NGS sequencing of BRCA1 and BRCA2 in FFPE-derived
tumour DNA
Sequencing of the BRCA1 and BRCA2 coding regions
was performed using the Ion Ampliseq BRCA1 and
BRCA2 panel on the Ion Torrent sequencing platform.
111 patients were successfully sequenced for BRCA1 and
BRCA2. BAM files were generated using Torrent Suite
v4.6, and variants called using the Torrent Variant Caller
v4.6.0.7. The minimum per-sample mean depth of cover-
age achieved was 916X; the median per-sample mean
depth achieved was 4728X. The median uniformity of
sequencing depth across targets was 90.5%. Called vari-
ants were functionally annotated using the Ensembl
Variant Effect Predictor Version 75.
Sequencing of FFPE-derived DNA presents the chal-
lenges of both fragmentation and spontaneous deamin-
ation of DNA associated with formalin fixation [28, 29].
Consistent with these fixation artefacts, we observed a bias
in the mutation spectrum of bi-allelic single nucleotide
variants (SNVs) in our study compared to those reported
in OC samples in the TCGA dataset, which utilised fresh
frozen material (Fig. 2a) [25]. Consistent with previous
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reports, the strongest bias was in cytosine to thymine
SNVs, likely as a result of cytosine deamination [29, 30].
To compensate for these artefacts, we applied mini-
mum allele frequency (AF) thresholding to the set of
variants. Comparing the proportion of previously docu-
mented (more likely true) variants retained to the pro-
portion of novel (more likely false) variants, we found
that for minimum AF > 10% more previously docu-
mented variants were lost than novel variants retained
(Fig. 2b). We also compared the mutation spectrum of
all retained bi-allelic SNVs at each AF threshold to the
mutation spectrum from the fresh frozen TCGA sam-
ples, showing that the majority of the bias was removed
at AF ≥ 10% (Table 1 and Additional file 1: Figure S1).
Together, these analyses demonstrated that a 10% AF
threshold removed a large proportion of likely erroneous
variants, while conserving the majority of likely true vari-
ants and minimising the difference in mutation spectrum
compared to the TCGA data. Accordingly, variants de-
tected at AF < 10% were discarded prior to analysis.
Classification of functionally relevant BRCA1 and BRCA2
variants
Frameshift and nonsense variants in BRCA1 and BRCA2
were classified as likely damaging to protein function, as
were previously reported missense mutations with known
pathogenicity. Splice site variants with reported pathogen-
icity were also classified as likely to be damaging. Missense
mutations predicted as unlikely to affect protein function
by both Sorting Intolerant From Tolerant (SIFT) and
PolyPhen scores were discarded as non-functional vari-
ants, while those predicted likely deleterious by both were
Fig. 1 Flow diagram of HGS OC patients evaluable for PLD response
Fig. 2 a Comparison of bi-allelic SNV spectra between DNA extracted from FFPE and fresh frozen material in the TCGA data. b Proportions of
previously documented variants retained (DVR) and novel variants removed (NVR) at various minimum allele frequency (AF) thresholds
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classified as likely to be damaging [31, 32]. Missense mu-
tations with conflicting SIFT and PolyPhen predictions
were discarded as variants of unknown significance.
Three insertion/deletion (indel) variants called at high
frequency across the cohort were identified as suspected
recurrent sequencing errors around homopolymer re-
gions. Sanger sequencing of these regions in the respective
tumours confirmed these as sequencing errors, consistent
with previous reports of false-positive indel calling around
problematic genomic regions on Ion Torrent NGS plat-
forms (Additional file 2: Table S1) [33].
PLD response data
Patient response data were obtained retrospectively from
the Edinburgh Ovarian Cancer Database. Responders
were defined as patients who showed partial or complete
CA125 tumour marker response or radiological response
(either WHO or RECIST criteria as some patients pre-
dated RECIST reporting) from the PLD chemotherapy
package. Patients who experienced stable disease, disease
progression, or succumbed to disease on therapy were
classified as non-responders. Patients for whom both
CA125 data and scans were not available, or who re-
ceived fewer than two cycles of PLD, were considered
unevaluable for PLD response (Fig. 1).
Results
BRCA1 and BRCA2 mutation frequency
Among the 111 successfully sequenced PLD-treated pa-
tients, 46 variants likely to affect protein function were de-
tected, comprising 26 BRCA1 variants and 20 BRCA2
variants. Of the BRCA1 variants, 12 were frameshift-
inducing indels and 14 were missense variants, including
11 instances of the missense-causing SNP rs1799950
conferring a Gln356Arg amino-acid change and predicted
to be detrimental to BRCA1 function by both SIFT and
PolyPhen. Of the BRCA2 variants, 10 were frameshift
indels, 7 were missense variants, 1 was a nonsense muta-
tion and 2 were splice site variants.
Across the study cohort 31.5% (35 of 111) of patients
harboured at least one variant in BRCA1 or BRCA2 pre-
dicted as likely to affect protein function (BRCA1/2-aber-
rant). Specifically, 20.7% (23 of 111 patients) harboured at
least one variant in BRCA1 alone, 9.9% (11 of 111) dis-
played at least one variant in BRCA2 alone, and 0.9% (1 of
111 patients) harboured variants in both BRCA1 and
BRCA2, consistent with previous reports of the higher
BRCA1 mutation frequency in OC versus BRCA2 [10].
Of the BRCA1/2-aberrant population, 97.1% (34 of 35)
were HGS OC, consistent with previous reports of the as-
sociation between BRCA1/2 mutation and HGS histology.
The remaining case was high grade endometrioid OC.
Patient demographics of BRCA1/2-aberrant and BRCA1/2
wild-type populations
There was no difference in FIGO stage at diagnosis, suc-
cess of primary surgical tumour debulking, platinum
sensitivity at PLD therapy initiation, or in the number of
lines of cytotoxic chemotherapy received prior to PLD
between the BRCA1/2-aberrant and wild-type groups
(Table 2). BRCA1/2-aberrant patients were significantly
younger at diagnosis compared with wild-type (median
55 years vs. 64 years, respectively; Welch Two-Sample t-
test p < 0.001), consistent with previous associations of
BRCA1/2 mutation with younger age at diagnosis [34].
PLD therapy response rate
78.4% (87 of 111) of patients were evaluable for response
to PLD. 19.5% (17 of 87) were classified as responders
by virtue of achieving either a CA125 or radiological re-
sponse. This observed response rate is comparable to
that reported in other studies investigating the use of
single agent PLD in the advanced-stage recurrent disease
setting [17, 18, 35].
Different histological subtypes of OC are known to dis-
play distinct response profiles to chemotherapy [36–38].
The vast majority of patients classified as responders had
disease of HGS histology (94.1%, 16 of 17), giving a re-
sponse rate of 19.3% (16 of 83) in the HGS population.
Table 1 Proportion of total SNVs accounted for by each SNV class at various minimum allele frequency (AF) thresholds and
corresponding sum of squares differences (SSD) in SNV mutation spectra between FFPE and fresh frozen TCGA data
Minimum AF threshold Proportion of variants in fresh frozen data
SNV no filter 0.05 0.1 0.15
A > C/T > G 0.017 0.026 0.054 0.051 0.061
A > G/T > C 0.100 0.165 0.286 0.372 0.126
A > T/T > A 0.015 0.023 0.009 0.013 0.087
C > A/G > T 0.017 0.026 0.063 0.064 0.186
C > G/G > C 0.012 0.023 0.036 0.051 0.175
C > T/G > A 0.839 0.737 0.554 0.449 0.366
SSD 0.287 0.193 0.102 0.103 0.000
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Given the limited number of non-HGS patients evaluable
for PLD response in this cohort (N = 4), comparison of
differential response rates to PLD between histological
OC groups could not be made.
BRCA1/2 status influences response rate to PLD in HGS OC
We observed a significantly higher response rate to PLD
in the BRCA1/2-aberrant HGS OC population compared
with the wild-type group in this study (Fig. 3) (36.0%, 9
of 25 patients vs. 12.1%, 7 of 58 patients; Fisher’s exact
test p = 0.016). Of the 9 responses in the BRCA1/2-aber-
rant population, two were radiological, 6 were CA125
tumour marker response, and one was both radiological
and CA125 response. Of the 7 responses in the wild-type
population, two were radiological, three were CA125
tumour marker response, and two were both radiological
and CA125 tumour marker response. This BRCA1/2-aber-
rant population comprised both BRCA1/2-mutant patients
and patients who harboured the predicted detrimental
rs1799950 BRCA1 SNP. When considering patients har-
bouring only rs1799950, we observed a significantly super-
ior response rate to PLD versus the wild-type population
(50%, 3 of 6 patients vs. 12.1%, 7 of 58; Fisher’s exact test
p = 0.044), despite the small numbers of patients in this
group (N = 6). There was a similar trend for superior re-
sponse rate to PLD in the BRCA1/2-mutant population
Table 2 Demographic of PLD-treated patients
BRCA1/2-Aberrant OC (n = 35) Wild-Type OC (n = 76) p-value
No. % No. %
Age at diagnosis, years
Median 55 64 <0.001a
Range 39–77 41–82
Histology
HGS 34 97.1 70 92.1
Endometrioid 1 2.9 2 2.6
Clear Cell 0 0 2 2.6
Mucinous 0 0 0 0.429b
LGS 0 0 0
Carcinosarcoma 0 0 2 2.6
FIGO stage at diagnosis
I 1 2.9 1 1.4
II 3 8.6 4 5.6
III 23 65.7 48 66.7 0.470c
IV 8 22.9 19 26.4
NA 0 0 4
Debulking status
<2 cm 14 42.4 23 31.5 0.282e
≥2 cm 19 57.6 50 68.5
NA 2 3
Platinum sensitivity at PLD initiation
Sensitive 5 15.2 9 12.5
Resistant 28 84.8 63 87.5 0.761d
NA 2 4
No. of chemotherapy lines prior to PLD
≤2 25 71.4 61 80.3 0.429e
>2 10 28.6 15 19.7
Evaluable for PLD response
Evaluable 26 74.3 61 80.3 0.644e
Not evaluable 9 15.7 15 19.7
aWelch Two Sample t-test; bFisher’s exact test, HGS versus non-HGS histology; cFisher’s exact test, early (I-II) versus advanced (III-IV) stage at diagnosis; dFisher’s
exact test; eChi-squared test; NA, not available
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following the exclusion of patients whose tumour har-
boured only rs1799950 (31.6%, 6 of 19 patients vs. 12.1%, 7
of 58 patients; Fisher’s exact test p = 0.075).
Discussion
Using NGS technology, we were able to sequence FFPE-
derived DNA for the BRCA1 and BRCA2 genes in 111
PLD-treated patients at high sequencing depth. We ob-
served a strong bias in the SNV spectrum of FFPE-
derived DNA versus that reported by the TCGA study
which utilised fresh frozen patient material, consistent
with formalin fixation-induced artefacts known to occur
in FFPE-derived DNA [29, 30]. We used a minimum al-
lele frequency cut-off threshold for called variants to
correct the mutation spectrum for these fixation arte-
facts. While this approach risks filtering a minority of
true variants, we have demonstrated that it removes the
bulk of fixation-associated artefacts, whilst retaining the
vast majority of likely true positive variants, achieving a
practical equipoise for variant filtering.
We detected 29 and 22 BRCA1 and BRCA2 sequence
variants likely to affect protein function, respectively.
Among these, we identified rs1799950, a BRCA1 SNP pre-
dicted to be deleterious to protein function by PolyPhen
and SIFT prediction tools. This SNP results in a non-
conservative amino acid change in BRCA1 protein: the
charged residue arginine is incorporated in place of the
uncharged residue glutamine at amino acid 356. A previ-
ous study of high-risk prostate cancer families found that
the minor allele of rs1799950 was associated with an in-
creased risk of developing prostate cancer (OR 2.25, 95%
confidence interval 1.21–4.20), but its relevance to treat-
ment response is unstudied [39]. Furthermore, homozy-
gosity of the minor allele state has previously been
associated with breast cancer risk in a population from
Saudi Arabia [40].
Of the 83 HGS OC patients evaluable for response to
PLD chemotherapy, 19.3% responded to PLD, concurring
with observations in previous studies [17, 18, 35]. Despite
the low number of responders (N = 16), we were able to
show a significantly superior response rate in those har-
bouring BRCA1/2 aberrations predicted damaging to pro-
tein function, when compared to BRCA1/2 wild-type
samples, of approximately 2.5-fold. This is consistent with
the hypothesis that impaired HRR function renders OC
sensitive to non-platinum DNA damaging agents such as
PLD, as well as platinum-based chemotherapy.
A minority of patients harboured the BRCA1 SNP
rs1799950 with no other detected BRCA1/2 defects.
While this group were severely limited by size, we ob-
served a greater than four-fold response rate in this popu-
lation compared to the wild type population. Notably, this
SNP was reported to possess a minor allele frequency of
0.0596 in European populations by the 1000 Genomes
Project, and would therefore be considered a common
variant according to population genetics conventions.
These data suggest that rs1799950 is biologically signifi-
cant in terms of response to cytotoxic chemotherapy, and
further characterisation of this variant is now warranted.
Future studies should seek to evaluate whether rs1799950,
and other common BRCA1 and BRCA2 variants, modu-
late sensitivity to platinum and other DNA damaging
agents in vitro, and address whether such variants convey
inherited susceptibility to malignancy, particularly to OC
and breast carcinoma.
Previous studies have shown that BRCA1-deficient OC
are more likely to display high levels of tumour infiltrat-
ing lymphocytes (TILs) and display an enrichment of
immune response genes [41]. OC with high levels of T
cell infiltration have superior clinical outcome, thought
to be secondary to an improved anti-tumoural immune
response [42, 43]. Recent work has suggested that PLD
may enhance the immune response in BRCA1-deficient
tumours [44], and this may contribute to the improved
benefit from PLD seen in BRCA1/2-aberrant tumours.
The higher response rate in BRCA1/2-aberrant patients
presents an additional argument for prospective BRCA1
and BRCA2 sequencing in all OC patients. Given the low
response rate to PLD in the BRCA1/2 wild-type popula-
tion (12.1% in our cohort), alternative therapies could be
considered for the treatment of patients who have had
Fig. 3 Differential response rate to PLD chemotherapy according to
BRCA1/2 status of sequenced tumour material. * indicates p < 0.05
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germline or somatic BRCA1 and BRCA2 sequencing and
have not displayed functionally relevant genetic changes
in either of these genes. In light of the high response rate
observed in BRCA1/2-aberrant patients, PLD should be
considered as an active treatment option in patients with
known BRCA1/2 mutations.
Moving forward, the question remains as to whether
this observed superior response rate extends to patients
with defects in other components of the HRR pathway.
In particular, detrimental variants in HRR genes known
to be mutationally inactivated in a minority of hereditary
OC – such as BRIP1, PALB2 and CHEK2 – may also
predict response rate to PLD. Furthermore, the impact
on PLD response rate, if any, of epigenetic silencing of
BRCA1 via promoter methylation remains unstudied.
Conclusion
HGS OC patients displaying BRCA1/2 sequence aberra-
tions predicted detrimental to BRCA1 or BRCA2 protein
function display an increased response rate to PLD. Pa-
tients harbouring the common BRCA1 variant rs1799950
may also display a superior response rate to PLD. These
data support the notion that HGS OC patients with
BRCA1/2 mutations are more sensitive to non-platinum
DNA damaging agents compared to their BRCA1/2 wild-
type counterparts. The role of rs1799950 in chemotherapy
sensitivity and predisposition to OC and BC warrants fur-
ther investigation.
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